AlphAIAlphAI — Financial news for AI agents
nationalmortgagenews.comSEP 113 min read$RCKT

Pulte moves give whole loan sellers reason to act on VS4

Federal Housing Finance Agency Director Bill Pulte's credit score modernization efforts are progressing, with lenders encouraged to add VantageScore 4.0 (VS4) data fields. Guild Mortgage's David Battany and Vice Capital Markets' Chris Bennett highlight the importance of adopting VS4 for future opportunities. GSEs have slowly increased VS4 activity, with Rocket Mortgage and United Wholesale Mortgage leading. Lenders are considering the benefits and risks of VS4, including potential cost savings a

Original reporting
nationalmortgagenews.com
Published Sep 11, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pulte moves give whole loan sellers reason to act on VS4 — source image
Source · nationalmortgagenews.com
Decision brief

The 30-second read

$RCKTBullishLow
01

Why it matters

Early adoption metrics suggest leading lenders like Rocket Mortgage and United Wholesale Mortgage stand to benefit, while the broader mortgage sector may see pricing shifts.

02

Market read

The rollout of VS4 could reshape loan‑level pricing and affect agency MBS valuations, with immediate relevance for top mortgage originators.

03

What to watch

Potential data‑mapping costs and investor readiness could slow broader VS4 integration despite early volume.

Relevance 6/10Novelty 6/10Timing: post‑August data release

Background

The FHFA and GSEs are modernizing credit scoring by introducing VantageScore 4.0, with pilot data now publicly reported.

Company-level read

Ticker impact

$RCKTBullishMedium confidence
Context

KBW report shows Rocket Mortgage accounted for 69.4% of VS4 volume in August, indicating its leading role in the new score adoption.

Expected impact

Potential upside as investors view early adoption as a competitive advantage.

Evidence & confidence

Early adoption data suggests Rocket Mortgage is positioned to benefit from broader VS4 rollout.

$FNMANeutralLow confidence
Context

Fannie Mae is also implementing VS4 and publishing historic credit data, influencing the agency MBS market.

Expected impact

Minimal short‑term stock movement; broader sector implications are more relevant.

Evidence & confidence

Policy implementation is a sector‑wide factor, not a unique catalyst for FNMA.

Market effects

Sector

Accelerated VS4 adoption may shift mortgage underwriting standards across the industry.

Regional

U.S. mortgage lenders and GSE‑backed securities could see pricing adjustments.

Global

Changes in U.S. agency loan scoring could influence global mortgage‑linked investment products.

Counterpoint

What could challenge this read

If VS4 fails to deliver lower credit costs, lenders may revert to traditional FICO, limiting upside for early adopters.

Key entities

  • Regulator
    Bill Pulte

    FHFA Director overseeing credit score modernization.

  • Research Firm
    Keefe, Bruyette & Woods

    Provided the August VS4 volume statistics.

Read at source← All news

Related articles

SEP 28
$FMCCMed

Freddie Mac: Multifamily Delinquency Rate Rises To Multi-Decade High

Fannie Mae and Freddie Mac reported August multifamily mortgage delinquencies. Freddie Mac's rate hit a 20-year high at 0.64%, up from 0.6% in July. Fannie Mae's rate fell to 0.57% from 0.62% in July. Rising delinquencies may reflect slowing rent growth and increased cost of living, according to Multifamily Dive and Urban Institute research.

zerohedge.com2 min
SEP 23
$RCKTHighAI 8/10

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

Rocket Pharmaceuticals (RCKT) announced FDA agreement to include 3 patients in its Phase 2 trial for Danon disease gene therapy RP-A501, with 9 more to be enrolled. The modified protocol includes dose adjustments and enhanced safety monitoring. The FDA confirmed 12-month co-primary endpoints for efficacy. The trial aims to complete dosing by mid-2027, with primary assessment 12 months post-treatment. Safety and efficacy data remain key uncertainties.

insidermonkey.com2 min
SEP 17
$RCKTMed

Refinancing all but vanishes as mortgage rates climb

Major U.S. mortgage lenders adjusted their 30-year fixed rates following the Federal Reserve's rate hike. Rocket Mortgage and Bank of America increased rates, while U.S. Bank lowered its. Freddie Mac reported a national average rate of 6.76%, with refinance applications dropping 9% week-over-week. Home-equity products saw increased interest, and the NAHB/Wells Fargo Housing Market Index fell to 32 in September.

aol.com3 min
SEP 16
$UNPMed

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Ulta Beauty (NASDAQ:ULT

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

benzinga.com2 min
SEP 16
$RCKTHighAI 8/10

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Rocket Pharmaceuticals (RCKT) received an FDA alignment on a pivotal study for its genetic disease therapy, leading to a 'Buy' upgrade from Needham with a $9 price target, implying 150% upside. The FDA confirmed continued enrollment in the Phase 2 study of RP-A501 for Danon Disease, with dosing expected to complete by mid-2027. The stock was up 7.6% on the news.

stocktwits.com2 min
SEP 16
$RCKTHighAI 8/10

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA

Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 price target after FDA approved the trial design for RP-A501, a gene therapy for Danon Disease. The FDA's modifications include dosing and patient inclusion criteria. RCKT has no revenue, a $375M market cap, and a GF Score of 25, indicating financial stability but operational challenges. Insiders sold $1.0M in shares over the past year, while institutional guru ownership remains steady.

gurufocus.com2 min